Emerging Infectious Disease ISSN: 1080-6059

Scale-up of Multidrug-Resistant Tuberculosis Laboratory Services, Peru

Sonya S. Shin*

, Martin Yagui†, Luis Ascencios†, Gloria Yale‡, Carmen Suarez‡, Neyda Quispe†, Cesar Bonilla‡, Joaquin Blaya§, Allison Taylor¶, Carmen Contreras#, and Peter Cegielski¶

Author affiliations: *Brigham and Women’s Hospital, Boston, Massachusetts, USA; †Instituto Nacional de Salud, Lima, Peru; ‡Programa de Control de Tuberculosis, Lima, Peru; §Partners in Health, Boston, Massachusetts, USA; ¶Centers for Disease Control and Prevention, Atlanta, Georgia, USA; #Socios en Salud, Lima, Peru;

Main Article

Figure 3

Description and costs of the direct Griess method in Peru. A) Pan-susceptible Mycobacterium tuberculosis isolate. B) M. tuberculosis isolate resistant to isoniazid (INH) and rifampin (RIF). The left (control) tube in panel A and all tubes in panel B indicate mycobacterial growth. The costs of the test are US $5.30 per sample, including personnel, materials (items that can be reused), and supplies (reagents and consumable items), and US $4.80 per sample, including materials and supplies.

Figure 3. Description and costs of the direct Griess method in Peru. A) Pan-susceptible Mycobacterium tuberculosis isolate. B) M. tuberculosis isolate resistant to isoniazid (INH) and rifampin (RIF). The left (control) tube in panel A and all tubes in panel B indicate mycobacterial growth. The costs of the test are US $5.30 per sample, including personnel, materials (items that can be reused), and supplies (reagents and consumable items), and US $4.80 per sample, including materials and supplies.

Main Article

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.